These include good performance status (5), adherence to treatment (6, 7), low tumor mutation burden (8), optimal cytoreductive surgery (9), post-treatment CA-125 normalization (10), BRCA1/2 mutations or homologous recombination deficiency (11, 12), long term sensitivity to platinum-based chemotherapy (13), use of PRPP inhibitors or anti-VEGF therapy (14), no residual disease (15), and stable mental well-being (16). Here, VEGFA is linked to neoplasm.